Altimmune (ALT) Stock Price, Quote, News & History | Benzinga

Altimmune Inc (ALT) Stock Price, Quote, News & History

ALTNASDAQ

Trade with Public

Trade with Public

$3.11

N/A

At close: Aug 24, 5:00 PM EST

$3.11

-0.0015-0.05%

After Hours: 7:41 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.13

Close

$3.11

Volume / Avg.

2.72M / 4.33M

Day Range

$3.03 - $3.13

52 Wk Range

2.56 - 6.44

Market Cap

$604.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

26.73%

Days to Cover

11.45

Recent Altimmune Inc News

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune reports positive Phase 2 RECLAIM trial data for pemvidutide in AUD and plans to request an EOP2 meeting with the FDA.

Vandana Singh

Why Is Altimmune Stock Falling Today?

Altimmune shares fall after a $225 million offering raises dilution concerns while funding key late-stage trials.

Nabaparna Bhattacharya

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock

Avi Kapoor

ASGN Posts Downbeat Q1 Results, Joins Medpace, ServiceNow And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures fall 200 pts, ASGN stock drops 25.2% after missing earnings estimates. Other stocks declining in pre-market trading. Photo: Shutterstock

Avi Kapoor

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune shares are tumbling on Wednesday following the company's announcement of a $75 million registered direct offering of common stock.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-76.51M

Investing Cash Flow (TTM)

-453.61M

Financing Cash Flow (TTM)

410.02M

Free Cash Flow (TTM)

-76.56M

Capital Expenditure (TTM)

-54.00K

Net Change in Cash (TTM)

-120.10M

Analyst Trends and Forecast

2

Mar

1

May

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$313.72M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

12660.41

PB Ratio (TTM)

1.27

Earnings Yield % (TTM)

-24.48%

Earnings Yield % (FWD)

-18.04%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.44

Company Debt

Total Debt

$34.74M

LT Debt

$34.74M

LT Debt Issuance (TTM)

$20.40M

LT Debt Repayment (TTM)

-

Total Cash

$63.01M

Debt to Equity

0.08

Issuance of Debt (TTM)

$20.40M

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.13

Close

$3.11

Volume / Avg.

2.72M / 4.33M

Day Range

$3.03 - $3.13

52 Wk Range

2.56 - 6.44

Market Cap

$604.66M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

56

Short Interest

26.73%

Days to Cover

11.45

About

Sector

Health Care

Industry

Biotechnology

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanc...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Altimmune (ALT) stock?

A

You can purchase shares of Altimmune (NASDAQ:ALT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Altimmune (ALT) competitors?

A

Other companies in Altimmune’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Altimmune (ALT) stock?

A

Altimmune has a consensus price target of $17.00.

Q

What is the current price for Altimmune (ALT)?

A

The stock price for Altimmune (NASDAQ: ALT) is $3.1085 last updated August 24, 2026 at 7:41 PM EDT.

Q

Does Altimmune (ALT) pay a dividend?

A

There are no upcoming dividends for Altimmune.

Q

When is Altimmune (NASDAQ:ALT) reporting earnings?

A

Altimmune does not have any upcoming earnings scheduled.

Q

Is Altimmune (ALT) going to split?

A

There is no upcoming split for Altimmune.

Q

What sector and industry does Altimmune (ALT) operate in?

A

Altimmune is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.